© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 2, 112-120,
January 17, 2001
© 2001 Oxford University Press
Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes
Affiliations of authors: B. Fisher, National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; J. Dignam, S. Anderson, Department of Biostatistics, University of Pittsburgh; E. Tan-Chiu, NSABP and Allegheny General Hospital, Pittsburgh; E. R. Fisher, NSABP and Allegheny General Hospital; J. L. Wittliff, University of Louisville Hormone Receptor Laboratory, KY; N. Wolmark, NSABP and Allegheny General Hospital.
Correspondence to: Bernard Fisher, M.D., Scientific Director, National Surgical Adjuvant Breast and Bowel Project, 4 Allegheny Center, Suite 602, Pittsburgh, PA 15212–5234 (e-mail: bernard.fisher{at}nsabp.org).
Background: Uncertainty about prognosis and treatment of axillary lymph node-negative patients with estrogen receptor (ER)-negative or ER-positive invasive breast tumors of 1 cm or less prompted the analysis of data from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. Methods: Two hundred thirty-five patients with ER-negative tumors and 1024 patients with ER-positive tumors were identified in these trials. Patients with ER-negative tumors received surgery alone or surgery and chemotherapy. Patients with ER-positive tumors received surgery alone; surgery and tamoxifen; or surgery, tamoxifen, and chemotherapy. End points were relapse-free survival (RFS), event-free survival, and overall survival. A result was considered to be statistically significant with a P value of .05 or less; all statistical tests were two-sided. Results: The 8-year RFS of women with ER-negative tumors who received surgery alone or with chemotherapy was 81% and 90%, respectively (P = .06). Survival was similar in both groups (93% and 91%; P = .65). The 8-year RFS of women with ER-positive tumors was 86% after surgery alone, 93% when tamoxifen was added (P = .01), and 95% after the addition of tamoxifen and chemotherapy (P = .07 compared with tamoxifen). Survival in the three groups was 90%, 92% (P = .41), and 97%, respectively. The difference between the latter two groups was significant (P = .01). Regardless of ER status or treatment, overall mortality was 8%; one half of the deaths were related to breast cancer. Several covariates affected the risk of recurrence in ER-negative and ER-positive patients. Risk was greater in women with tumors of 1 cm than in those with tumors of less than 1 cm, in women aged 49 years or younger than in those aged 50 years or older, and in women with infiltrating ductal or lobular carcinoma than in those with other histologic tumor types. Conclusions: Chemotherapy and/or tamoxifen should be considered for the treatment of women with ER-negative or ER-positive tumors of 1 cm or less and negative axillary lymph nodes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. B. Marks, J. Zeng, and L. R. Prosnitz One to Three Versus Four or More Positive Nodes and Postmastectomy Radiotherapy: Time to End the Debate J. Clin. Oncol., May 1, 2008; 26(13): 2075 - 2077. [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, A. M. Gonzalez-Angulo, S. H. Giordano, R. Rouzier, K. R. Broglio, G. N. Hortobagyi, and V. Valero Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma J. Clin. Oncol., November 1, 2007; 25(31): 4952 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Noguchi, H. Koyama, J. Uchino, R. Abe, S. Miura, K. Sugimachi, K. Akazawa, and O. Abe Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials J. Clin. Oncol., April 1, 2005; 23(10): 2172 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. van't Veer, S. Paik, and D. F. Hayes Gene Expression Profiling of Breast Cancer: A New Tumor Marker J. Clin. Oncol., March 10, 2005; 23(8): 1631 - 1635. [Full Text] [PDF]
|
|
|
|
|
|
S. Dellapasqua, M. Colleoni, R. D. Gelber, and A. Goldhirsch Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1736 - 1750. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. O'Regan Do Tumors Detected by Mammography Screening Have a Favorable Prognosis? JAMA, September 1, 2004; 292(9): 1062 - 1063. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cykert, N. Phifer, and C. Hansen Tamoxifen for Breast Cancer Prevention: A Framework for Clinical Decisions Obstet. Gynecol., September 1, 2004; 104(3): 433 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Agrawal and E. J. Emanuel Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data JAMA, August 27, 2003; 290(8): 1075 - 1082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. L. Du, C. Osborne, and J. S. Goodwin Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer J. Clin. Oncol., December 15, 2002; 20(24): 4636 - 4642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Whelan A Trial of Two Questions J. Clin. Oncol., October 15, 2002; 20(20): 4135 - 4138. [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, J. Bryant, J. J. Dignam, D. L. Wickerham, E. P. Mamounas, E. R. Fisher, R. G. Margolese, L. Nesbitt, S. Paik, T. M. Pisansky, et al. Tamoxifen, Radiation Therapy, or Both for Prevention of Ipsilateral Breast Tumor Recurrence After Lumpectomy in Women With Invasive Breast Cancers of One Centimeter or Less J. Clin. Oncol., October 15, 2002; 20(20): 4141 - 4149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ganz Breast Cancer 2002: Where Do We Stand? CA Cancer J Clin, September 1, 2002; 52(5): 253 - 255. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ganz, K. A. Desmond, B. Leedham, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study J Natl Cancer Inst, January 2, 2002; 94(1): 39 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fisher, J.-H. Jeong, J. Dignam, S. Anderson, E. Mamounas, D. L. Wickerham, and N. Wolmark Findings From Recent National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies in Stage I Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bergh and M. Holmquist Who Should Not Receive Adjuvant Chemotherapy? International Databases J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 103 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Querci della Rovere and J. R. Benson Re: Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes J Natl Cancer Inst, September 19, 2001; 93(18): 1420 - 1420. [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher and J. J. Dignam RESPONSE: Re: Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes J Natl Cancer Inst, September 19, 2001; 93(18): 1421 - 1422. [Full Text] [PDF]
|
|
|
|
|
|
D. Mirchandani and F. Muggia Re: Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes J Natl Cancer Inst, September 19, 2001; 93(18): 1420a - 1421a. [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer J. Clin. Oncol., September 15, 2001; 19(18): 3817 - 3827. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Swain Tamoxifen for Patients With Estrogen Receptor-Negative Breast Cancer J. Clin. Oncol., September 15, 2001; 19(90001): 93s - 97. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz and G. A. Greendale Menopause and Breast Cancer: Addressing the Secondary Health Effects of Adjuvant Chemotherapy J. Clin. Oncol., July 15, 2001; 19(14): 3303 - 3305. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Lippman and D. F. Hayes Adjuvant Therapy for All Patients With Breast Cancer? J Natl Cancer Inst, January 17, 2001; 93(2): 80 - 82. [Full Text] [PDF]
|
|